ProCE Banner Activity

Phase III J-ALEX: Alectinib vs Crizotinib in ALK Inhibitor–Naïve, ALK-Positive NSCLC

Slideset Download
Conference Coverage
J-ALEX met its primary endpoint--alectinib significantly improved PFS vs crizotinib with a favorable safety profile in ALK inhibitor–naive patients with ALK-positive NSCLC.

Released: June 10, 2016

Expiration: June 09, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals